Compare Cadila Healthcare with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs AUROBINDO PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE AUROBINDO PHARMA CADILA HEALTHCARE/
AUROBINDO PHARMA
 
P/E (TTM) x 14.4 11.0 131.2% View Chart
P/BV x 2.8 2.4 117.9% View Chart
Dividend Yield % 1.5 0.5 277.6%  

Financials

 CADILA HEALTHCARE   AUROBINDO PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
AUROBINDO PHARMA
Mar-18
CADILA HEALTHCARE/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs558809 69.0%   
Low Rs362504 71.7%   
Sales per share (Unadj.) Rs116.3281.1 41.4%  
Earnings per share (Unadj.) Rs17.941.4 43.2%  
Cash flow per share (Unadj.) Rs23.150.9 45.5%  
Dividends per share (Unadj.) Rs3.502.50 140.0%  
Dividend yield (eoy) %0.80.4 199.9%  
Book value per share (Unadj.) Rs85.4199.4 42.8%  
Shares outstanding (eoy) m1,023.74585.88 174.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.02.3 169.3%   
Avg P/E ratio x25.715.9 162.1%  
P/CF ratio (eoy) x19.912.9 154.0%  
Price / Book Value ratio x5.43.3 163.5%  
Dividend payout %19.66.0 324.0%   
Avg Mkt Cap Rs m470,664384,630 122.4%   
No. of employees `00011.817.3 68.2%   
Total wages/salary Rs m18,54521,308 87.0%   
Avg. sales/employee Rs Th10,072.79,500.7 106.0%   
Avg. wages/employee Rs Th1,569.11,229.4 127.6%   
Avg. net profit/employee Rs Th1,547.71,397.9 110.7%   
INCOME DATA
Net Sales Rs m119,049164,666 72.3%  
Other income Rs m1,1321,020 111.0%   
Total revenues Rs m120,181165,686 72.5%   
Gross profit Rs m28,47537,718 75.5%  
Depreciation Rs m5,3885,580 96.6%   
Interest Rs m911777 117.2%   
Profit before tax Rs m23,30832,380 72.0%   
Minority Interest Rs m62831 2,000.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6448,183 69.0%   
Profit after tax Rs m18,29224,229 75.5%  
Gross profit margin %23.922.9 104.4%  
Effective tax rate %24.225.3 95.8%   
Net profit margin %15.414.7 104.4%  
BALANCE SHEET DATA
Current assets Rs m82,005121,878 67.3%   
Current liabilities Rs m60,72086,806 69.9%   
Net working cap to sales %17.921.3 83.9%  
Current ratio x1.41.4 96.2%  
Inventory Days Days73130 56.3%  
Debtors Days Days9868 143.8%  
Net fixed assets Rs m83,70381,037 103.3%   
Share capital Rs m1,024586 174.8%   
"Free" reserves Rs m86,421116,218 74.4%   
Net worth Rs m87,445116,804 74.9%   
Long term debt Rs m25,5514,512 566.3%   
Total assets Rs m180,653211,052 85.6%  
Interest coverage x26.642.7 62.3%   
Debt to equity ratio x0.30 756.4%  
Sales to assets ratio x0.70.8 84.5%   
Return on assets %10.611.8 89.7%  
Return on equity %20.920.7 100.8%  
Return on capital %22.027.4 80.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,68380,727 52.9%   
Fx outflow Rs m11,24234,700 32.4%   
Net fx Rs m31,44146,027 68.3%   
CASH FLOW
From Operations Rs m9,19319,548 47.0%  
From Investments Rs m-9,737-19,570 49.8%  
From Financial Activity Rs m5158,642 6.0%  
Net Cashflow Rs m-298,922 -0.3%  

Share Holding

Indian Promoters % 74.8 54.1 138.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 8.0 104.4%  
FIIs % 5.9 27.7 21.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.2 107.8%  
Shareholders   44,069 69,601 63.3%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Oct 18, 2019 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - FULFORD INDIA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS